USD 12.1 billion
Report ID:
SQMIG35G2114 |
Region:
Global |
Published Date: February, 2025
Pages:
219
|Tables:
62
|Figures:
78
Global Cancer Tumor Profiling Market size was valued at USD 12.1 billion in 2023 and is poised to grow from USD 13.44 billion in 2024 to USD 31.2 billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).
The growth of cancer around the world and the use of biomarkers in tumor profiling are the primary factors driving the market for cancer detection and treatment products. The increase in cancer research and funding initiatives and technological advancements has led to the growth of the cancer/tumor profiling market. The growth of personalized medicine and point-of-care diagnostics is forecast to offer significant opportunities for market players during the next few years.
The cancer/tumor profiling market is not expected to be significantly impacted by the COVID-19 pandemic in 2020-2021. The COVID-19 outbreak has caused a significant decrease in cancer testing and diagnosis due to measures taken to protect against the virus. During the forecast period the cancer/tumor profiling market is including into genomics, proteomics, epigenetics, and metabolomics, Out of these, genomics is forecast to have the highest CAGR (19.7%) . The technique is used for the characterization of genes; it determines whether a gene in the complete genome is normal or abnormal. Mutations are responsible for the abnormal development of genes, which can help cancer cells survive. Cancer tumor profiling is a potential procedure for detecting and further studying cancer to identify changes in tumor stage, metabolism, and morphology.
US Cancer Tumor Profiling Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2025-2032
Global Market Size
USD 12.1 billion
Largest Segment
genomic biomarker
Fastest Growth
protein biomarker
Growth Rate
11.1% CAGR
To get more reports on the above market click here to Buy The Report
Global Cancer Tumor Profiling Market is segmented by Cancer type, Biomarker type, Technology, Technique, Application and region. Based on Cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer. Based on Biomarker type, the market is segmented into Genomic Biomarker and Protein Biomarker. Based on Technology, the market is segmented into Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays and Others. Based on Technique, the market is segmented into Genomics, Proteomics, Metabolomics and Epigenetics. Based on Application, the market is segmented into Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening and Treatment and Monitoring. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the technology, the immunoassays segment accounted for the largest market share in 2021. These tests are used as a standard to conduct tumor profiling on a large scale, helping measure the presence and concentration of analytes in a sample. These tests are used for cancer diagnosis, prognosis, and treatment decisions. The tests used in clinical settings can help shorten hospital stays and decrease the severity of illnesses by identifying and assessing the progression of the disease. This information can then lead to improved therapeutic choices.
Based on the cancer type, the breast cancer segment accounted for the largest share of the cancer/tumor profiling market, ensured by lung cancer. Breast cancer is the major factor contributing to the large share of the cancer tumor profiling market. The lung cancer segment is expected to reach its highest level during the forecast period. The increasing incidence of lung cancer worldwide is helping to support the growth of this segment.
Based on the biomarker type, The large share of genomic biomarker is due to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process. The protein biomarkers segment is estimated to grow at a high rate over the next few years as more researchers adopt proteomic methods for biomarker research. This will help speed up drug development processes.
To get detailed analysis on other segments, Request For Free Sample Report
North America is estimated to account for the largest share in terms of revenue owing to the presence of major players and rapid advances in technology. The high prevalence of cancer and the increasing research in oncology will lead to increased market growth in the treatment of cancer. The large share of the regional market for these diagnostic kits is due in large part to the quick uptake of advanced technologies by the firms manufacturing these kits.
Asia Pacific is a lucrative region, with expected steady growth over the next few years due to its large untapped markets and population pool.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Incidences of Cancer to Bolster Market Growth
Technical Issues might Hinder Market Growth
Request Free Customization of this report to help us to meet your business objectives.
The market for cancer/tumor profiling products is growing, with new companies coming up with new ways to make money. MDNA Life Sciences Inc. launched its liquid biopsy Prostate Mitomic Test in May 2017 in the United States. Together with Helomics Corp., this test is designed to help doctors diagnose prostate cancer. The test uses the unique genetic characteristics of mitochondrial DNA, and it is exclusively available at Helomics' clinical laboratories. In April 2017, Helomics Corporation also launched its Dynamic Clinical Health Insight Platform (D-CHIP), which can be used to study the detailed information related to cancer patients' genomes, proteins, DNA, and RNA in order to identify more-effective biomarkers for pharmaceutical and diagnostic companies.
Sky Quest's ABIRAW (Advanced Business Intelligence, Research and Analysis Wing) is our Business Information Services team that collects, collates, Co-relates and analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to our Global Cancer Tumor Profiling Market analysis, Increasing investment in research & development, particularly in developed and developing nations, will further open up attractive market expansion potential for medical instruments and technologies. The market growth rate is also being supported by research and development efforts being made to improve the whole process of cancer detection and treatment as well as to integrate cutting-edge technologies into healthcare facilities.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 12.1 billion |
Market size value in 2032 | USD 31.2 billion |
Growth Rate | 11.1% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Cancer Tumor Profiling Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Tumor Profiling Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Tumor Profiling Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cancer Tumor Profiling Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Cancer Tumor Profiling Market size was valued at USD 11.87 Billion in 2023 and is poised to grow from USD 13.13 Billion in 2024 to USD 29.39 Billion by 2032, growing at a CAGR of 10.6% during the forecast period (2025-2032).
The market for cancer/tumor profiling products is growing, with new companies coming up with new ways to make money. MDNA Life Sciences Inc. launched its liquid biopsy Prostate Mitomic Test in May 2017 in the United States. Together with Helomics Corp., this test is designed to help doctors diagnose prostate cancer. The test uses the unique genetic characteristics of mitochondrial DNA, and it is exclusively available at Helomics’ clinical laboratories. In April 2017, Helomics Corporation also launched its Dynamic Clinical Health Insight Platform (D-CHIP), which can be used to study the detailed information related to cancer patients’ genomes, proteins, DNA, and RNA in order to identify more-effective biomarkers for pharmaceutical and diagnostic companies. 'Illumina, Inc.', 'Thermo Fisher Scientific, Inc.', 'QIAGEN N.V.', 'F. Hoffmann-La Roche AG', 'Agilent Technologies, Inc.', 'Myriad Genetics, Inc.', 'Personal Genome Diagnostics Inc.', 'Foundation Medicine, Inc.', 'Guardant Health, Inc.', 'NanoString Technologies, Inc.', 'Genomic Health, Inc.', 'Adaptive Biotechnologies Corporation', 'Caris Life Sciences', 'Becton, Dickinson and Company', 'PerkinElmer, Inc.', 'Natera, Inc.', 'Oxford Nanopore Technologies', 'Biocartis Group NV', 'ArcherDX, Inc.', 'Sysmex Corporation', 'Haystack Oncology Inc. was purchased by US-based medical laboratory Quest Diagnostics in June 2023 for a sum of $450 million. With this acquisition, Quest Diagnostics hopes to improve research and development* capabilities, boost market share in cancer diagnostics, and broaden access to liquid biopsy technologies. An early-stage cancer company in the US is called Haystack Oncology Inc.', 'Thermo Fisher Scientific introduced the "Oncomine Dx Express Test" and "Oncomine Reporter Dx" with the "Ion Torrent Dx System" in September 2022. These CE-IVD (IVDD) tests are intended for use in clinical labs to provide clinically relevant biomarker results in a single day and to increase the company's access to precision oncology biomarker testing.', 'To market its range of genetic tests, Avesthagen Limited and Wipro Limited signed a four-year strategic collaboration in June 2022. Genome panels, which provide extremely specialized, disease-centric analysis for ailments like cancer, autoimmune disorders, neurodegenerative diseases, and uncommon disease situations, are part of the portfolio.'
Increase in cancer incidences is one of the major contributors to market growth in the complete cancer/tumor profiling market. the increasing burden of cancer can be attributed to various factors, Cancer is a complex and widespread disease, caused by a variety of factors. Population growth and aging, as well as the changing prevalence of certain causes of cancer, are all contributors to its prevalence.
The trends in the cancer/tumor profiling market is the Integration of omics data and advances in liquid biopsy tests is expected to grow at the highest CAGR during the forecast period. Personalized medicine is a growing field of healthcare research that is changing the way diseases are identified, classified, and treated. It has now become mainstream clinical practice, and is being used to treat many different diseases. The advances in cancer care are particularly apparent in the area of oncology.
North America is estimated to account for the largest share in terms of revenue owing to the presence of major players and rapid advances in technology. The high prevalence of cancer and the increasing research in oncology will lead to increased market growth in the treatment of cancer. The large share of the regional market for these diagnostic kits is due in large part to the quick uptake of advanced technologies by the firms manufacturing these kits.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35G2114
[email protected]
USA +1 351-333-4748